NCT04147650View on ClinicalTrials.gov

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

September 17, 2020

Study Completion Date

October 8, 2020

Conditions
Dry Eye SyndromeKeratoconjunctivitis Sicca
Interventions
DRUG

0.05% Voclosporin Ophthalmic Solution (VOS)

0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

DRUG

0.10% VOS

0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

DRUG

0.20% VOS

0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks

Trial Locations (9)

16066

Aurinia Investigative Center, Cranberry Township

37205

Aurinia Investigative Center, Nashville

38119

Aurinia Investigative Center, Memphis

40206

Aurinia Investigative Center, Louisville

80907

Aurinia Investigative Center, Colorado Springs

92663

Aurinia Investigative Center, Newport Beach

04240

Aurinia Investigative Center, Lewiston

01810

Aurinia Investigative Center, Andover

02767

Aurinia Investigative Center, Raynham

Sponsors
All Listed Sponsors
lead

Aurinia Pharmaceuticals Inc.

INDUSTRY